ClinicalTrials.gg
RecruitingNCT07362186Updated May 11, 2026

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

A Phase 3 interventional study of LM-108 in combination with Toripalimab and Paclitaxel injection intravenous infusion in Locally Advanced or Metastatic GC and GCJ Adenocarcinoma, sponsored by LaNova Medicines Limited. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase III, Multicenter, Randomized study, evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.

02

Conditions studied

  • Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
03

In context

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals who are willing to participate in the study and sign the form (ICF) prior to any procedure.
  2. Age 18 years or older, male or female.
  3. Weight ≥ 40 kg or (BMI)≥ 18.5 kg/m²
  4. (ECOG) performance status of 0-1.
  5. ≥ 3 months.
  6. Individuals must have or cytologically confirmed locally advanced or gastric/gastroesophageal junction adenocarcinoma and be ineligible for curative surgery or radiotherapy.
  7. Confirmed CCR8-positive by the central laboratory.
  8. -negative, low-expressing, or non-expressing.
  9. Individuals must experience radiographic progression during or after prior standard therapy, or who developed intolerance to treatment due to chemotherapy-related toxicity
  10. At least one lesion.
  11. Have appropriate organ and marrow function in laboratory examinations.
  12. Women of have a negative pregnancy test and must not be breastfeeding. All of agree to use effective throughout the study period and for 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Received treatment targeting the same target or other drugs acting on regulatory T cells (Tregs).
  2. Received antitumor treatments such as chemotherapy, radiotherapy, biological therapy, immunotherapy, or Chinese herbal medicine or Chinese herbal preparations within 2-4 weeks (depending on the specific anticancer drug) prior to the first dose.
  3. Received anti-PD-(L)1 antibody immunotherapy and experienced disease progression confirmed by 1.1 assessment within ≤2 months after treatment initiation.
  4. Use of any within 4 weeks prior to the first dosing of study drugs.
  5. Individuals who received major surgery or interventional treatment within 4 weeks prior to the first dosing of study drugs.
  6. Individuals who take systemic (> 10 mg daily prednisone equivalents) or other systemic medications within 2 weeks prior to the first dosing of study drugs.
  7. Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of v6.0, individuals who experienced ≥ Grade 3 immune-related adverse events during prior immunotherapy, or terminated prior immunotherapy due to severe or life-threatening immune-related adverse events.
  8. Any other pathological type.
  9. Uncontrollable clinical third-space fluid accumulation.
  10. Unstable or progressive central nervous system (CNS) or carcinomatous meningitis (meningeal metastases).
  11. Individuals with a known history of diseases.
  12. For individuals with drug allergies or .
  13. The investigator determined that there are other situations that are not suitable for participation in this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    LM-108 in combination with Toripalimab

    Drug: LM-108 in combination with Toripalimab

  • Active comparator
    Paclitaxel injection intravenous infusion

    Drug: Paclitaxel injection intravenous infusion

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS was defined as the time from date of randomization until death from any cause

    Time frame: up to 42 months

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from date of randomization until first objective radiographic tumor progression or death from any cause, based on Investigator assessment

    Time frame: up to 42 months

  2. Objective response rate (ORR)

    ORR is defined as the proportion of subjects achieving the best overall response (BOR) of CR or PR. BOR refers to the best response recorded during the period from the date of randomization to the date of objective progression documented according to RECIST 1.1 criteria or the date of initiation of subsequent antitumor therapy (whichever occurs first).

    Time frame: up to 42 months

  3. Duration of response (DOR)

    defined time from the initial response (CR or PR) until documented tumor progression or death from any cause and based on Investigator assessment.

    Time frame: Time from initial response (CR or PR) to date of documented disease progression or death (due to any cause) whichever occurs first, up to 42 months

  4. Disease control rate (DCR)

    defined as the proportion of participants who achieved CR, PR, or stable disease (SD) , based on Investigator assessment.

    Time frame: From start of treatment to date of documented disease progression, up to approximately 42 months

  5. Incidence of adverse events (AEs)

    Time frame: up to 42 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Aug 2028, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 23, 2026
StartActual
Apr 30, 2026
Primary completionEst.
Aug 17, 2028
CompletionEst.
Sep 28, 2028
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07362186
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Apr 30, 2026
Primary completion
Aug 17, 2028 (estimated)
Completion
Sep 28, 2028 (estimated)
Last update
May 11, 2026

Study contacts

Mengmeng Liu
Contact
mengmengliu@lanovamed.com
+86 13918118040
Paul Kong
Contact
paulkong@lanovamed.com
+86 13564682439
Lin Shen
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cafelkibart · Toripalimab

Start the discussion